**Additional file 6.** Schedule of blood/serum collection

|  |  |  |  |
| --- | --- | --- | --- |
| **Sample purpose** | **Administration** | **Day** | **Sampling time-point (acceptable range)** |
| Blood: circulating CD16-positive NK cells  | Cycles 1 and 2 | 1 | Before administration (day of administration)4 h after start of administration (± 20 min) |
|  |  | 2 | 24 h after start of administration (± 2 h) |
| Blood: *HLA/KIR* mismatch, NK activity (Step 2 only) | - | - | Before the first dose of DS-8895a |
| Blood: blood cell markers, marker for blood cell activation (Step 2 only) | - | - | Before the first dose of DS-8895a |
|  | Cycle 1 | 3 | 48 h after start of administration (± 2 h) |
| Serum: Cytokines | Cycles 1 and 2 | 1 | Before administration (day of administration)At completion (± 15 min)4 h after start of administration (± 20 min)7 h after start of administration (± 20 min) |
|  |  | 2 | 24 h after start of administration (± 2 h) |
| Serum: Soluble EPHA2 | Cycle 1 | 1 | Before administration (day of administration) |
| (Step 2 only) |  | 4 | 72 h after start of administration (± 2 h) |
|  |  | 8 | (± 1 day) |
|  |  | 15 | Before administration (day of administration) |
|  | Cycle 2 | 8 | (± 1 day) |

Abbreviations: NK cells, natural killer cells; HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor; EPHA2; erythropoietin-producing hepatocellular receptor A2